A method for managing delivery of medication to a patient including medication dosage control and medication flow rate control for the patient. The method comprises controlling flow rate of the medication to be delivered to the patient through a needle that is subcutaneously inserted into the patient including: monitoring glucose levels in the patient using a continuous glucose monitoring device; converting the glucose levels from the continuous glucose monitoring device into instructions by control algorithms within a microcontroller unit; commanding a pumping unit to deliver the medication through the needle at a flow rate based on the converted instructions; and delivering the medication through the needle into the patient at the flow rate; and adjusting the flow rate continually to reduce a difference between actual flow rate measured off of the pumping unit and a converted flow rate from the continuous glucose monitoring device.

Method and system for providing basal profile modification in insulin therapy for use with infusion devices includes periodically monitoring the analyte levels of a patient for a predetermined period of time in order to determine, based on the monitored analyte levels, an appropriate modification factor to be incorporated into the underlying basal profile which was running at the time the periodic monitoring of the analyte levels were performed.

The present invention provides a closed loop control method in an artificial pancreas and a system using the method, comprising sensing an activity level of a patient by at least one motion sensor and providing signals to at least one processer; then adjusting a series of related algorithms depending partly on the signals by the processer to provide more accurate and reliable data that is the basis of desirable treatment plans, and sending corresponding instructions by the processer for automatic operations of the artificial pancreas to realize a closed loop control.

A blood glucose monitoring and controlling system includes a detecting device and a liquid supplying device. The detecting device includes a first microneedle patch, a liquid pumping actuator, a sensor and a monitoring and controlling chip. The liquid supplying device includes a second microneedle patch, a liquid supplying actuator, a liquid supplying chamber and a liquid supplying and controlling chip. The detecting device is used to measure the blood glucose level of the user, and the liquid supplying device is used to supply insulin liquid. While the detecting device measures that the blood glucose level of the user is abnormal, the liquid supplying device is actuated to inject the insulin liquid into the user's body, thereby stabilizing the user's blood glucose level constantly.

Systems and methods for treating a medical condition such as worsening heart failure (WHF) are described. A medical system may sense one or more physiological signals, and generate from the sensed physiological signals a signal metric trend indicating a progression of heart failure. A detector may detect a physiological event leading to WHF. A therapy control circuit may generate a therapy titration protocol using the generated signal metric trend. The therapy titration protocol includes a temporal profile of therapy dosage relative to a target dosage. The therapy control circuit may adjust the target dosage based on patient response. Therapies may be administered by a clinician or automatically delivered to the patient according to the therapy titration protocol.

Disclosed herein are techniques related to medicine administration in dynamic networks. The techniques may involve identifying an amount of medicine for delivery to a patient and determining a communication path toward a first medicine administration device of a plurality of medicine administration devices in a mesh network. The plurality of medicine administration devices may further include a second medicine administration device that is prioritized over the first medicine administration device for delivering medicine to the patient. The techniques may further involve causing delivery of the amount of medicine to the patient by the first medicine administration device based on communicating the amount of medicine toward the first medicine administration device via the communication path when the amount of medicine remains undelivered by the second medicine administration device.

Systems and method for monitoring the blood glucose concentration of a patient during a hemodialysis session and automated administration of a medication in response to the glucose concentration falling outside a specified range. The system includes a hemodialysis system and a glucose sensor. The hemodialysis system includes a control system, at least one medication infusion pump, and a dialyzer fluidly connectable to a venous patient line and an arterial patient line. The glucose sensor is in communication with the control system and positioned to continuously measure the blood glucose concentration of the patient during the hemodialysis session. The control system can be programmed to provide automated administration of medication by the at least one medication infusion pump in response to changes in the blood glucose concentration of the patent during the hemodialysis session.

The disclosed embodiments are directed to methods for adjusting, on a per individual basis, the maximum delivery limit of insulin delivered to a diabetic person via an automatic insulin delivery system, particularly for a diabetic who receives basal or bolus doses of insulin via an automatic insulin delivery system. Various embodiments of the method disclosed herein may be incorporated into a dosing algorithm of an automatic insulin delivery system.

The disclosed embodiments are directed to methods for determining, based on input from a manual insulin delivery device, for example, an insulin pen, a proper bolus dosing to be delivered by an AID system, to assess the sufficiency of the user-administered basal dose of long-acting insulin and to recommend any changes to the long-acting delivery following a daily analysis of the user's blood glucose readings.

This invention relates to an ingestible drug delivery device configured for wireless communication with other ingestible drug delivery devices.